https://vitasmlab.net

CELDIMARK

Celiac Disease Targeted Library

Celiac disease is an autoimmune disorder triggered by gluten ingestion, damaging the small intestine and impairing nutrient absorption. It affects approximately 1% of the global population, causing symptoms like diarrhea, weight loss, fatigue, and long-term complications such as osteoporosis, infertility, and increased cancer risk. The only current treatment is a strict, lifelong gluten-free diet, which is challenging to maintain, socially restrictive, and often insufficient to prevent symptoms or intestinal damage. This underscores the urgent need for new therapeutic options. Developing drugs targeting celiac disease could alleviate symptoms, promote intestinal healing, and improve quality of life. Such advancements would address unmet medical needs, reduce healthcare burdens, and offer hope for patients struggling with dietary limitations. Drug discovery research is vital to transform celiac disease management and provide effective, accessible solutions.



Example Targets:

Transglutaminase 2

JAK Kinase Myosin light chain kinase



STK776414



STK759829



STK922729

Celiac Disease Targeted Library (CELDIMARK) consists of compounds which were selected based on similarity to known effectors of proteins, associated with celiac disease. This library was designed to provide a potential starting point or to expand ongoing drug discovery project. It is designed in a way that maximizes structural diversity and excludes problematic compounds. This library has 3435 compounds. All compounds follow RO5.

Distribution of Parameters



If you have any specific needs for your project, we can provide specially tailored compound library based on your request.

Have questions or need a quote? Contact Irina Haywood (Ryabushenko) at
irina@vitasmlab.biz
Let's Connect on LinkedIn! Expand your professional network.

We look forward to collaborating with you!
Empowering Your Research, One Molecule at a Time.